000168486 001__ 168486
000168486 005__ 20260209162330.0
000168486 0247_ $$2doi$$a10.3390/antibiotics9010019
000168486 0248_ $$2sideral$$a116493
000168486 037__ $$aART-2020-116493
000168486 041__ $$aeng
000168486 100__ $$0(orcid)0000-0001-9262-2461$$aMorte-Romea, E.$$uUniversidad de Zaragoza
000168486 245__ $$aPerformance assessment of software to detect and assist prescribers with antimicrobial drug interactions: Are all of them created equal?
000168486 260__ $$c2020
000168486 5060_ $$aAccess copy available to the general public$$fUnrestricted
000168486 5203_ $$aBackground: Detecting and managing antimicrobial drug interactions (ADIs) is one of the facets of prudent antimicrobial prescribing. Our aim is to compare the capability of several electronic drug–drug interaction (DDI) checkers to detect and report ADIs. Methods: Six electronic DDI checking platforms were evaluated: Drugs.com®, Medscape®, Epocrates®, Medimecum®, iDoctus®, and Guía IF® . Lexicomp® Drug Interactions was selected as the gold standard. Ten ADIs addressing different mechanisms were evaluated with every electronic DDI checker. For each ADI, we assessed five dimensions and calculated an overall performance score (maximum possible score: 10 points). The explored dimensions were sensitivity (capability to detect ADI), clinical effect (type and severity), mechanism of interaction, recommended action(s), and documentation (quality of evidence and availability of references). Results: The electronic DDI checkers did not detect a significant proportion of the ADI assessed. The overall performance score ranged between 4.4 (Medimecum) and 8.8 (Drugs.com). Drugs.com was the highest ranked platform in four out of five dimensions (sensitivity, effect, mechanism, and recommended action). Conclusions: There is significant variability in the performance of the available platforms in detecting and assessing ADI. Although some ADI checkers have proven to be very accurate, others missed almost half of the explored interactions. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
000168486 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000168486 590__ $$a4.639$$b2020
000168486 591__ $$aPHARMACOLOGY & PHARMACY$$b76 / 275 = 0.276$$c2020$$dQ2$$eT1
000168486 591__ $$aINFECTIOUS DISEASES$$b26 / 92 = 0.283$$c2020$$dQ2$$eT1
000168486 592__ $$a0.96$$b2020
000168486 593__ $$aBiochemistry$$c2020$$dQ1
000168486 593__ $$aInfectious Diseases$$c2020$$dQ1
000168486 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2020$$dQ1
000168486 593__ $$aMicrobiology (medical)$$c2020$$dQ1
000168486 593__ $$aPharmacology (medical)$$c2020$$dQ1
000168486 593__ $$aMicrobiology$$c2020$$dQ1
000168486 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168486 700__ $$0(orcid)0000-0001-7790-409X$$aLuque-Gómez, P.
000168486 700__ $$aArenere-Mendoza, M.
000168486 700__ $$0(orcid)0000-0002-8796-2717$$aSierra-Monzón, J. L.$$uUniversidad de Zaragoza
000168486 700__ $$aPueyo, A. C.$$uUniversidad de Zaragoza
000168486 700__ $$aSagastizabal, G. P.$$uUniversidad de Zaragoza
000168486 700__ $$aMuñoz, G. V.
000168486 700__ $$aFabra, D. S.
000168486 700__ $$0(orcid)0000-0002-9600-8116$$aPaño-Pardo, J. R.$$uUniversidad de Zaragoza
000168486 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168486 773__ $$g9, 1 (2020), 19 [8 pp]$$pAntibiotics$$tAntibiotics$$x2079-6382
000168486 8564_ $$s477150$$uhttps://zaguan.unizar.es/record/168486/files/texto_completo.pdf$$yVersión publicada
000168486 8564_ $$s2528744$$uhttps://zaguan.unizar.es/record/168486/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168486 909CO $$ooai:zaguan.unizar.es:168486$$particulos$$pdriver
000168486 951__ $$a2026-02-09-14:41:55
000168486 980__ $$aARTICLE